Prof. Dr. NEBİ SERKAN DEMİRCİ

Yayın Ağı

Makaleler 41

1. Prognostic Impact of the Lung Immune Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab

Bedir Ş., Kapağan T., Bozkaya Y., Oyman A., Fidan M. C., Guliyev M., et al.

Cancers , cilt.18, sa.7, 2026 (SCI-Expanded, Scopus)

2. Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab

Güren A. K., DEMİRCAN N. C., GÜMÜŞAY Ö., Şimşek E. T., Kemik F., KARAOĞLU Ç., et al.

Immunotherapy , cilt.18, sa.4, ss.317-326, 2026 (SCI-Expanded, Scopus)

3. Clinicopathological Predictors of Axillary Pathological Complete Response and Its Prognostic Significance in Clinically Node-Positive (cN+), HER2-Positive Breast Cancer Following Neoadjuvant Therapy

Bedir Ş., Yeşilova U. A., Tokoçin M., Çakan Demirel B., Bozkaya Y., Oyman A., et al.

Medicina (Lithuania) , cilt.62, sa.1, 2026 (SCI-Expanded, Scopus)

4. Stage II colon cancer: does ChatGPT recommend more intensive adjuvant therapy? A comparison with MDT decisions.

Birsin Z., Jeral S., Cebeci S., Çerme E., Aliyev V., Günaltılı M., et al.

Future oncology (London, England) , ss.1-8, 2025 (SCI-Expanded, Scopus)

5. Inflammatory and Nutritional Markers Predicting Pathological Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Multicenter Real-World Study

Birsin Z., Nazli I., Alkan O., ODABAŞI BÜKÜN H., Gunaltili M., Cerme E., et al.

JOURNAL OF CLINICAL MEDICINE , cilt.14, sa.20, 2025 (SCI-Expanded, Scopus)

6. Comparative Efficacy and Cost-Effectiveness of Denosumab Versus Zoledronic Acid in Cancer Patients with Bone Metastases

Aliyev V., Guliyev M., Gunaltili M., Fidan M. C., Cerme E., Abbasov H., et al.

JOURNAL OF CLINICAL MEDICINE , cilt.14, sa.18, 2025 (SCI-Expanded, Scopus)

7. Sorafenib vs chemotherapy in the treatment of locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: real-world data from Turkey.

Majidova N., Aghamaliyeva S., Guliyev M., Dinc G., AKYILDIZ A., Ozcan E., et al.

Journal of chemotherapy (Florence, Italy) , cilt.37, sa.8, ss.735-740, 2025 (SCI-Expanded, Scopus)

8. Obesity Is an Independent Prognostic Factor That Reduced Pathological Complete Response in Operable Breast Cancer Patients.

Guliyev M., Alan Ö., Günaltılı M., Safarov S., Fidan M. C., Alkan Şen G., et al.

Medicina (Kaunas, Lithuania) , cilt.60, sa.12, 2024 (SCI-Expanded, Scopus)

9. The impact of HER2-low status on pathological complete response and disease-free survival in early-stage breast cancer.

Şen G. A., AYDIN E., Guliyev M., Öztaş N. Ş., Değerli E., DEMİRCİ N. S., et al.

BMC cancer , cilt.24, sa.1, ss.1311, 2024 (SCI-Expanded, Scopus)

10. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)

Akyildiz A., GÜVEN D. C., Koksal B., KARAOĞLAN B. B., Kivrak D., Ismayilov R., et al.

EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY , cilt.281, sa.9, ss.4991-4999, 2024 (SCI-Expanded, Scopus)

11. Prognostic factors in Kaposi sarcoma, single centre experience

Değerli E., Oruç K., Şentürk Öztaş N., Alkan Şen G., Bedir Ş., DEMİRCİ N. S., et al.

Australasian Journal of Dermatology , cilt.65, sa.5, ss.444-450, 2024 (SCI-Expanded, Scopus)

12. Levels of Anxiety and Depression in Patients with Cancer During the COVID-19 Pandemic

ŞENGÜL N., BEDİR S., ÇELİK E., İÇLİ T. B., KAVLA Y., TURAN S., et al.

Eurasian Journal of Medical Investigation , cilt.8, sa.2, ss.98-105, 2024 (TRDizin)

13. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: A retrospective multi-center study by the Turkish Oncology Group (TOG).

Akyildiz A., Guven D. C., Koksal B., Karaoglan B. B., Salim D. K., Sutcuoglu O., et al.

JOURNAL OF CLINICAL ONCOLOGY , sa.16, 2024 (SCI-Expanded, Scopus)

14. The effects of low HER2 expression on survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: a multicenter retrospective study

Guliyev M., Şen G. A., Gültürk İ., Majidova N., Akdağ G., Ahadzade A., et al.

BREAST CANCER RESEARCH AND TREATMENT , cilt.205, sa.3, ss.633-640, 2024 (SCI-Expanded, Scopus)

15. Clinicopathologic Analysis and Prognostic Factors for Survival in Patients with Operable Ampullary Carcinoma: A Multi-Institutional Retrospective Experience

DEMİRCİ N. S., Cavdar E., Ozdemir N. Y., Yuksel S., Iriagac Y., ERDEM G. U., et al.

MEDICINA-LITHUANIA , cilt.60, sa.5, 2024 (SCI-Expanded, Scopus)

16. Clinicopathological Characteristics and Real-life Data of Patients Receiving Tyrosine Kinase Inhibitor in Metastatic EGFR Mutant Non-small Cell Lung Carcinoma

EKİNCİ B., DEMİRCİ N. S.

NAMIK KEMAL MEDICAL JOURNAL , sa.4, ss.385-394, 2023 (ESCI, TRDizin)

17. Major and minor salivary gland cancers: A multicenter retrospective study.

Hacioglu M. B., ERDOĞAN B., Bardakcı M., Algın E., Gulbagcı B., Hacibekiroglu I., et al.

Head & neck , cilt.45, sa.7, ss.1643-1653, 2023 (SCI-Expanded, Scopus)

18. Is the serum level of survivin, an antiapoptotic protein, a potential predictive and prognostic biomarker in metastatic pancreatic cancer?

DEMİRCİ N. S., Çavdar E., Erdem G. U., Hatipoglu E., Celik E., Sezer S., et al.

Medicine (United States) , cilt.102, sa.25, 2023 (SCI-Expanded, Scopus)

19. Relationship between pathological response and molecular subtypes in locally advanced breast cancer patients receiving neoadjuvant chemotherapy

DEĞERLİ E., ŞENTÜRK ÖZTAŞ N., ALKAN G., Bedir S., Derin S., VALIKHANOVA N., et al.

JOURNAL OF CHEMOTHERAPY , cilt.35, sa.1, ss.29-38, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

20. Decrease in estimated glomerular filtration rates in non-small cell lung cancer patients treated with crizotinib

Iriagac Y., Cavdar E., Karaboyun K., Tacar S. Y., Mustafayev F. N. A., Celik E., et al.

Journal of Cancer Research and Therapeutics , cilt.19, sa.2, ss.376-381, 2023 (SCI-Expanded, Scopus)

21. Bevacizumab-induced isolated oculomotor nerve palsy in glioblastoma multiforme

DEĞERLİ E., ALKAN G., ŞENTÜRK ÖZTAŞ N., Bedir S., Derin S., DEMİRCİ N. S.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.28, sa.3, ss.746-749, 2022 (SCI-Expanded, Scopus)

22. Breast cancer to thyroid gland: An unconventional metastatic site

Celik E., ÖZTÜRK T., Samanci N. S., DEMİRCİ N. S., Akovali B., DEMİRELLİ F. H.

Journal of Cancer Research and Therapeutics , cilt.18, sa.3, ss.788-791, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

23. The Relationship Between Symptom Severity and Caregiver Burden in Cancer Patients Under Palliative Care: A Cross-Sectional Study

ÇELİK E., ASLAN M. Ş., ŞENGÜL SAMANCI N., Karadag M., Saglam T., Celik Y. C., et al.

JOURNAL OF PALLIATIVE CARE , cilt.37, sa.1, ss.48-54, 2022 (SCI-Expanded, SSCI, Scopus) Sürdürülebilir Kalkınma

24. Use of volumetric CT scanning to predict tumor staging and survival in pancreatic cancer patients that are to be administered curative resection

ŞENGÜL SAMANCI N., ÇELİK E., BAĞCILAR Ö., TUTAR O., SAMANCI C., VELİDEDEOĞLU M., et al.

JOURNAL OF SURGICAL ONCOLOGY , cilt.123, sa.8, ss.1757-1763, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

25. THE EFFECTS OF COVID-19 PHOBIA ON QUALITY OF LIFE: A CROSS-SECTIONAL STUDY OF CANCER PATIENTS

Dönmez E., Temiz G., Dülger Z., Bayram Z., Berker Döğer B., Acar O., et al.

World Cancer Research Journal , cilt.8, 2021 (ESCI, Scopus)

26. Independent prognostic value of inflammation in metastatic pancreatic cancer.

Oksuzoglu B., Esin E., Koksoy E. B., Demirci N. S., Sendur M. A. N., Dede I., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.36, sa.15, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

27. Preoperative platelet-to-lymphocyte ratio is a predictor of prognosis in patients with ampullary carcinoma

Demirci N. S., Ozdemir N. Y., Erdem G. U., Bozkaya Y., Yazici O., Zengin N.

BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY , cilt.119, sa.3, ss.180-186, 2018 (SCI-Expanded, Scopus)

28. Queries for the article entitled "Predictors for extensive nodal involvement in breast cancer patients with axillary lymph node metastases"

Erdem G. U., Sahin S., Karatas F., Aytekin A., Demirci N. S., Yazilitas D.

BREAST , cilt.36, ss.104-105, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

29. Is plasma caveolin-1 level a prognostic biomarker in metastatic pancreatic cancer?

Demirci N. S., Dogan M., Erdem G. U., Kacar S., Turhan T., KILIÇKAP S., et al.

SAUDI JOURNAL OF GASTROENTEROLOGY , cilt.23, sa.3, ss.183-189, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

30. Comparative study of receptor discordance between primary and corresponding metastatic lesions in breast cancer.

Erdem G. U., Altundag K., Ozdemir N. Y., Sahin S., Demirci N. S., Karatas F., et al.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology , cilt.22, ss.365-376, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

31. Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study

Demirci N. S., AKSOY S., Ozdemir N. Y., Erdem G. U., Ozcelik M., Tanrikulu E., et al.

CURRENT MEDICAL RESEARCH AND OPINION , cilt.33, sa.3, ss.401-407, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

32. Comparison of clinicopathological and prognostic characteristics in patients with mucinous carcinoma and signet ring cell carcinoma of the stomach

Bozkaya Y., Erdem G. U., Ozdemir N. Y., Demirci N. S., Hocazade C., Yazici O., et al.

CURRENT MEDICAL RESEARCH AND OPINION , cilt.33, sa.1, ss.109-116, 2017 (SCI-Expanded, Scopus)

33. The efficacy of modified docetaxel-cisplatin-5-fluorouracil regimen as first-line treatment in patients with alpha-fetoprotein producing gastric carcinoma

Bozkaya Y., Dogan M., Yazici O., Erdem G. U., Demirci N. S., Zengin N.

BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES , cilt.17, sa.2, ss.138-143, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

34. Prognostic Effect of Symptomatic and Asymptomatic Venous Thromboembolism in Patients with Gastric Cancer

Bozkaya Y., Ozdemir N., Demirci N. S., Erdem G. U., Yazici O., Arslan S., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.27, sa.2, ss.100-109, 2017 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

35. The Determinants of Profitability in Manufacturing Industry Sector: Panel Data Analysis with CBRT Sectoral Balance Sheets (1996-2015)

Demirci N. S.

EGE ACADEMIC REVIEW , cilt.17, sa.3, ss.381-393, 2017 (ESCI, TRDizin) Sürdürülebilir Kalkınma

36. The clinical and pathological features affecting the time of relapse in patients with early stage colorectal cancer

Yazilitas D., Ozdemir N., Yazici O., Hocazade C., Demirci N. S., Zengin N.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , cilt.12, sa.4, ss.1257-1260, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

37. Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology

Odabas H., Ulas A., Aydin K., İNANÇ M., Aksoy A., Yazilitas D., et al.

TUMOR BIOLOGY , cilt.36, sa.12, ss.9641-9648, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

38. A rare case: Hallucination associated with pazopanib

Demirci N. S., Erdem G. U., Dogan M., Ozdemir N. Y., Zengin N.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , cilt.11, sa.4, ss.961-962, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

39. Rectal Cancer With Metastasis to the Face

Yazilitas D., Dogan M., Ileri A. B., Ozdemir N., Demirci N. S., Zengin N.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.25, sa.2, ss.145-147, 2015 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

40. Can targeted programmed death-1 antibody be a new treatment approach in breast cancer.

Sendur M. A. N., Aksoy S., Demirci S., Ozdemir N. Y., Zengin N., Altundag K.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology , cilt.19, ss.584, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

41. IS SECOND LINE SYSTEMIC CHEMOTHERAPY BENEFICIAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)? : A MULTICENTER DATA EVALUATION OF ANATOLIAN SOCIETY OF MEDICAL ONCOLOGY (ASMO)

Odabas H., Ulas A., Aydin K., İNANÇ M., Aksoy A., Yazilitas D., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.8, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 10

1. Modified epirubicin and oxaliplatin plus capecitabine (EOX) Regimen as second-line therapy after failure of modified docetaxel and cisplatin plus fuorouracil (DCF) regimen in advanced gastric cancer

Bozkaya Y., Yazici O., Ozdemir N., Erdem G. U., Demirci N. S., Zengin N.

42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, İspanya, 8 - 12 Eylül 2017, cilt.28, (Özet Bildiri) Sürdürülebilir Kalkınma

2. Plasma caveolin-1 level: A prognostic marker for pancreatic cancer.

Demirci N. S., Dogan M., Erdem G. U., Kacar S., Turhan T., Yilmaz F. M., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34, (Özet Bildiri) Sürdürülebilir Kalkınma

3. Modified docetaxel, cisplatin and fluorouracil therapy as a first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study.

Demirci N. S., Aksoy S., Ozdemir N., Babacan T., Erdem G. U., Bozkaya Y., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34, (Özet Bildiri) Sürdürülebilir Kalkınma

4. Clinicopathologic analysis and prognostic factors for survival in early stage patients with ampullary carcinoma.

Ozdemir N., Demirci N. S., Yuksel S., Erdem G. U., Odabas H., Boruban M. C., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34, (Özet Bildiri)

5. Comparative study of receptor expression diversity between primary and recurrent lesions in patients with metastatic breast cancer.

Erdem G. U., Ozdemir N., Sahin S., Demirci N. S., Karatas F., Bozkaya Y., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34, (Özet Bildiri) Sürdürülebilir Kalkınma

6. Effect of adding taxane to platin-5-fluorouracil combination on survival in elderly patients with advanced gastric cancer: A retrospective-multicenter study.

Gunaldi M., Kose F., Demirci N. S., Gundur S., Ozdemir N., Kocoglu H., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34, (Özet Bildiri) Sürdürülebilir Kalkınma

7. The importance of thiol/disulphide homeostasis in patients with advanced gastric cancer (AGC) receiving modified docetaxel and cisplatin plus fluorouracil (mDCF) regimen

Yazici O., Ozdemir N., EREL Ö., Demirci N. S., AKSOY S., ŞENDUR M. A. N., et al.

European Cancer Congress, Vienna, Avusturya, 01 Ocak 2015, cilt.51, (Özet Bildiri) Sürdürülebilir Kalkınma

8. The importance of thiol/disulphide homeostasis in patients with advanced colorectal cancer receiving modified fluorouracil and leucoverin plus oxaliplatin (mFOLFOX) regimen

Yazici O., Dogan M., EREL Ö., Bozkaya Y., Ozdemir N., Demirci N. S., et al.

European Cancer Congress, Vienna, Avusturya, 01 Ocak 2015, cilt.51, (Özet Bildiri) Sürdürülebilir Kalkınma

9. Operated and early stage ampulla vateri tumours: Prognostic assessment

Yildirim N., Mulazimoglu E., Yuksel S., Demirci N. S., Erdem G. U., Odabas H., et al.

European Cancer Congress, Vienna, Avusturya, 01 Ocak 2015, cilt.51, (Özet Bildiri)

10. The effect of body mass index on prognosis and survival of ER(-) and PR(+) nonmetastatic breast cancer patients: Single institute experience.

Dogan M., Erdem G. U., Demirci N. S., Zengin N.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) Sürdürülebilir Kalkınma

Metrikler

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

278

H-İndeks (WoS)

Atıf (Scopus)

341

H-İndeks (Scopus)

Atıf (Scholar)

H-İndeks (Scholar)

Açık Erişim

BM Sürdürülebilir Kalkınma Amaçları

Yayınlar & Eserler

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Atıf (Scholar)

H-İndeks (Scholar)

Açık Erişim